The company reported a loss of -38 cents a share for the second quarter, missing the Capital IQ Consensus Estimate of -36 cents a share by 2 cents. Revenue fell -29.2$ year-over-year to $6.84 million for the quarter. Analysts expected revenue of $15.75 million in the quarter.
Must read: Warren Buffett's 25 Favorite Stocks
TheStreet Ratings team rates IRONWOOD PHARMACEUTICALS INC as a Sell with a ratings score of D. TheStreet Ratings Team has this to say about their recommendation:
"We rate IRONWOOD PHARMACEUTICALS INC (IRWD) a SELL. This is driven by multiple weaknesses, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. The area that we feel has been the company's primary weakness has been its deteriorating net income."